These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27822706)

  • 1. Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
    Dragoj M; Milosevic Z; Bankovic J; Tanic N; Pesic M; Stankovic T
    Cell Oncol (Dordr); 2017 Feb; 40(1):47-62. PubMed ID: 27822706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.
    Dragoj M; Bankovic J; Sereti E; Stojanov SJ; Dimas K; Pesic M; Stankovic T
    Invest New Drugs; 2017 Dec; 35(6):718-732. PubMed ID: 28733702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.
    Chen YL; Yang TY; Chen KC; Wu CL; Hsu SL; Hsueh CM
    Cell Oncol (Dordr); 2016 Oct; 39(5):411-433. PubMed ID: 27306525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells.
    Su L; Zhang J; Xu H; Wang Y; Chu Y; Liu R; Xiong S
    Clin Cancer Res; 2005 Dec; 11(23):8273-80. PubMed ID: 16322285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.
    Cao Z; Liang N; Yang H; Li S
    Cell Prolif; 2017 Oct; 50(5):. PubMed ID: 28762597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
    Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
    J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
    Aboubakar Nana F; Lecocq M; Ladjemi MZ; Detry B; Dupasquier S; Feron O; Massion PP; Sibille Y; Pilette C; Ocak S
    Mol Cancer Ther; 2019 Jan; 18(1):17-27. PubMed ID: 30352800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
    Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
    J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.
    Datta A; Bhasin N; Kim H; Ranjan M; Rider B; Abd Elmageed ZY; Mondal D; Agrawal KC; Abdel-Mageed AB
    Cancer Lett; 2015 Jun; 362(1):25-35. PubMed ID: 25796439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.
    Bao YX; Zhao XD; Deng HB; Lu CL; Guo Y; Lu X; Deng LL
    Cell Oncol (Dordr); 2016 Aug; 39(4):343-52. PubMed ID: 27016208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway.
    Fu QF; Liu Y; Fan Y; Hua SN; Qu HY; Dong SW; Li RL; Zhao MY; Zhen Y; Yu XL; Chen YY; Luo RC; Li R; Li LB; Deng XJ; Fang WY; Liu Z; Song X
    J Hematol Oncol; 2015 Mar; 8():22. PubMed ID: 25887760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of cisplatin resistance in non-small cell lung cancer stem cells by Taxus chinensis var.
    Jiang YQ; Xu XP; Guo QM; Xu XC; Liu QY; An SH; Xu JL; Su F; Tai JB
    Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-199a-5p is involved in doxorubicin resistance of non-small cell lung cancer (NSCLC) cells.
    Jin Y; Wang H; Zhu Y; Feng H; Wang G; Wang S
    Eur J Pharmacol; 2020 Jul; 878():173105. PubMed ID: 32278855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enterolactone alters FAK-Src signaling and suppresses migration and invasion of lung cancer cell lines.
    Chikara S; Lindsey K; Borowicz P; Christofidou-Solomidou M; Reindl KM
    BMC Complement Altern Med; 2017 Jan; 17(1):30. PubMed ID: 28068967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer.
    Pozzato C; Outeiro-Pinho G; Galiè M; Ramadori G; Konstantinidou G
    EMBO Mol Med; 2024 Oct; 16(10):2402-2426. PubMed ID: 39271958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of PTPN13 in invasion and metastasis of lung squamous cell carcinoma.
    Han X; Xue L; Zhou L; Gong L; Zhu S; Yao L; Wang S; Lan M; Li Y; Zhang W
    Exp Mol Pathol; 2013 Dec; 95(3):270-5. PubMed ID: 23906871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells.
    Punia R; Raina K; Agarwal R; Singh RP
    PLoS One; 2017; 12(8):e0182870. PubMed ID: 28859099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.